Tripartite motif-containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen-activated protein kinase kinase kinase 7

Review Gastroenterology & Hepatology

Therapeutic pipeline in nonalcoholic steatohepatitis

Raj Vuppalanchi et al.

Summary: The therapeutic pipeline for NASH is expanding with insights into disease pathophysiology, offering potential solutions to resolve steatohepatitis or reverse fibrosis. However, there may be some clinical challenges in the use of these emerging therapies.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease

Nadia Akawi et al.

Summary: This study demonstrates that ceramides derived from adipose tissue can modulate vascular redox state in obesity, directly impacting cardiac mortality in patients with advanced atherosclerosis. Exogenous ceramides can increase vascular oxidative stress and inflammation, leading to adverse cardiovascular outcomes. Treatment with liraglutide in obese patients can suppress ceramide levels, potentially reducing the risk of cardiac mortality.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiology and risk-stratification of NAFLD-associated HCC

George N. Ioannou

Summary: NAFLD is projected to be the leading cause of hepatocellular carcinoma and is associated with risk factors such as obesity, diabetes, Hispanic ethnicity, and genetic polymorphisms. Lipotoxicity and oxidative DNA damage may lead to hepatocarcinogenesis, especially in the absence of cirrhosis. Validated models to identify high-risk patients for hepatocellular carcinoma in NAFLD are currently unavailable.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

Add to Collection

Article Gastroenterology & Hepatology